The 2025 International Summit on Human Genome Editing called for: • A moratorium on heritable edits until safety and societal consensus are achieved Meanwhile, patients with devastating genetic ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

ZUG, Switzerland and BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

America's next wave of scientific talent may come from Lambert High School, where students used CRISPR to develop a promising ...

The launch of BIRSA 101 marks a major breakthrough in CRISPR gene-editing technology, positioning India to deliver affordable ...

CRISPR Therapeutics (NASDAQ:CRSP) gains visibility as biotechnology activity aligns with broader movements across the Nasdaq ...

The CRISPR-Cas9 gene-editing tool is as much in the spotlight as it is under scrutiny. Researchers are eager to make genetic modifications to DNA across ...

At the heart of this technology is the Cas9 protein, often likened to molecular scissors, capable of cutting strands of DNA at specific locations dictated by a single guide RNA. With this mechanism, ...

CRISPR Therapeutics (CRSP) shares have seen considerable movement over the past month, leaving investors assessing what might be driving sentiment around this gene editing pioneer. With no recent ...

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the ...